Struggling biotechs succumb to icy market, as money dries up and clinical bets don’t pay off
In the span of 15 days, the fate of iTeos Therapeutics soured quickly. Once a beacon of the anti-TIGIT class, the company this spring faced two major issues: a key clinical failure for its cancer ...
In the span of 15 days, the fate of iTeos Therapeutics soured quickly.
Once a beacon of the anti-TIGIT class, the company this spring faced two major issues: a key clinical failure for its cancer ...
